Cencora Completes €1 Billion Senior Notes Sale

Cencora ( (COR) ) has issued an update.

On May 22, 2025, Cencora, Inc. completed the sale of €1 billion in senior notes, split equally between 2.875% notes due in 2028 and 3.625% notes due in 2032. These notes are unsecured and unsubordinated obligations, with specific terms outlined in the Indentures, which include limitations on creating liens, sale and leaseback transactions, and mergers. The issuance of these notes is significant for Cencora’s financial strategy, potentially impacting its market positioning by providing liquidity while imposing certain operational constraints.

The most recent analyst rating on (COR) stock is a Hold with a $245.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.

Spark’s Take on COR Stock

According to Spark, TipRanks’ AI Analyst, COR is a Outperform.

Cencora is performing strongly with robust revenue growth, operational efficiency, and effective cost management. The high leverage is a notable risk, but the company’s strategic focus on expanding its specialty medication offerings and raising guidance reflects confidence in future performance. The technical analysis and valuation suggest caution, as the stock may be experiencing consolidation, and the high P/E ratio points to potential overvaluation.

To see Spark’s full report on COR stock, click here.

More about Cencora

Average Trading Volume: 1,883,793

Technical Sentiment Signal: Buy

Current Market Cap: $56.78B

For detailed information about COR stock, go to TipRanks’ Stock Analysis page.